ArticlePediatric research2026
Hypoxanthine-early biomarker of outcomes in an ovine model of neonatal hypoxic ischemic encephalopathy.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypoxic-ischemic encephalopathy (HIE) is the leading cause of neonatal morbidity and mortality globally. An early tool to diagnose and prognosticate disease could aid in timely intervention and reduction in disease burden. We aimed to identify biomarkers for HIE and define whether these biomarkers are associated with neurologic outcome severity in our ovine model.
methodsStudy Cohort 1 (n = 46) included lambs with HIE induced via umbilical cord occlusion (UCO) and healthy controls (n = 19). Cohort 2 (n = 25 UCO lambs) served as a validation cohort for identified biomarkers. Blood samples collected at multiple early time points were analyzed using untargeted liquid chromatography-mass spectrometry. Biomarkers were considered significant at p < 1e-6. Neurological outcome biomarkers were identified using ordinal logistic regression.
resultsA total of 145 hypoxia biomarkers were identified, exhibiting a consistent and reproducible temporal pattern across both cohorts. Hypoxanthine level at 20 min of life showed a strong correlation with the severity of neurologic outcomes.
conclusionsHypoxanthine emerged as a significant neurologic outcome biomarker in our study. Our findings support the potential utility of metabolomics for early diagnosis and prognostication in HIE. Further clinical validation is warranted to translate these biomarkers into accessible diagnostic and predictive tools, particularly for resource-limited settings. IMPACT: Our study identified plasma hypoxanthine as an early biomarker for hypoxic-ischemic encephalopathy (HIE) in an ovine model and uncovered a novel correlation between hypoxanthine levels and the severity of neurologic impairment in asphyxiated lambs. These findings highlight the potential of metabolomics in the early detection of HIE, paving the way for improved diagnostic and prognostic strategies. Translating these insights into clinical practice could enable the development of predictive tools for outcome assessment and resource allocation, ultimately enhancing early intervention and optimizing care for neonates at risk of HIE.
Identifiers
41912893What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.